文献速递免疫规划慢病防控与筛查

中国四川不同HPV疫苗接种状态女性高危型HPV感染率研究

Prevalence of high-risk human papillomavirus among women with different HPV-vaccination status in Sichuan, China.
PubMed 文献 · Vaccine · 2026-02-27

该横断面研究分析2022至2024年四川6971名20-40岁常规妇科检查女性的宫颈标本,总体高危型HPV感染率为11.12%。接种2/4价或9价疫苗分别使HPV 16/18感染率降低60.5%和59.8%,但9价疫苗接种者非疫苗靶型高危HPV感染率显著高于未接种者。接种者CIN2+发生率显著低于未接种者。

要点

  • 接种2/4价或9价HPV疫苗使HPV 16/18感染率分别降低60.5%和59.8%。
  • 9价疫苗接种者非疫苗靶型高危HPV感染率6.88%,显著高于未接种者4.49%。
  • 接种者CIN2+发生率(2/4价1.97%;9价1.16%)显著低于未接种者3.60%。

核心结论

  • HPV疫苗有效降低疫苗型感染和CIN2+病变发生率,但9价疫苗接种者非疫苗靶型高危HPV感染率显著增加。

研究设计与样本

  • 横断面研究,分析2022至2024年四川6971名20-40岁常规妇科检查女性的宫颈标本。

主要发现

  • 总体高危型HPV感染率为11.12%(775/6971)。
  • 接种2/4价疫苗使HPV 16/18感染率降低60.5%(RR=0.395,95%CI:0.280-0.558)。
  • 接种9价疫苗使HPV 16/18感染率降低59.8%(RR=0.402,95%CI:0.277-0.583)。
  • 9价疫苗接种者非疫苗靶型高危HPV(35/39/51/56/59/66/68)感染率为6.88%,未接种者为4.49%(p<0.05)。
  • CIN2+发生率:接种2/4价者1.97%,接种9价者1.16%,未接种者3.60%(p<0.05)。

临床怎么用

  • 研究结果可为中国宫颈癌筛查策略和疫苗接种规划提供证据参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

While HPV vaccination has significantly reduced HPV 16/18 prevalence in other countries, HPV vaccination was not approved in China until 2016, most of those vaccinated are over the age of 20, the efficacy remains unknown. In this cross-sectional study, we analyzed cervical specimens from 6971 women (20-40 years) undergoing routine gynecological check-ups (2022-2024). The Overall HR-HPV prevalence was 11.12% (775/6971). Vaccination reduced HPV 16/18 prevalence by 60.5% (RR = 0.395, 95% CI: 0.280-0.558) with the 2/4-valent vaccine and 59.8% (RR = 0.402, 95% CI: 0.277-0.583) with the 9-valent vaccine. However, non-vaccine-targeted HR-HPV types (35/39/51/56/59/66/68) were more frequent in 9-valent recipients (6.88% vs. 4.49% in unvaccinated women, p < 0.05), offsetting the decline in overall HR-HPV prevalence. CIN2+ incidence was significantly lower in vaccinated (2/4-valent: 1.97%; 9-valent: 1.16%) than unvaccinated women (3.60%, p < 0.05). These results demonstrate that HPV vaccines effectively reduced vaccine-type infections and the incidence of CIN2+ lesions. It is worth to mention that the prevalence of non-vaccine-targeted HPV types has demonstrated a significant increase. These findings provide compelling evidence to inform cervical cancer screening strategies and vaccination programs in China.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Lixia H, Liangcheng X, Tian T, et al. Prevalence of high-risk human papillomavirus among women with different HPV-vaccination status in Sichuan, China. Vaccine. 2026. PMID: 41762971. doi:10.1016/j.vaccine.2026.128387

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。